Business Description
Arcturus Therapeutics Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US03969T1097
Total Employee Number:
111Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.81 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.13 | |||||
Beneish M-Score | -4.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.4 | |||||
3-Year Book Growth Rate | -9.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -12.77 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.72 | |||||
9-Day RSI | 25.49 | |||||
14-Day RSI | 31.92 | |||||
3-1 Month Momentum % | -16.84 | |||||
6-1 Month Momentum % | 0.96 | |||||
12-1 Month Momentum % | -45.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.31 | |||||
Quick Ratio | 6.31 | |||||
Cash Ratio | 6.15 | |||||
Days Sales Outstanding | 80.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 4.21 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -208.64 | |||||
Net Margin % | -185.75 | |||||
EBITDA Margin % | -177.07 | |||||
FCF Margin % | -138.52 | |||||
OCF Margin % | -138.3 | |||||
ROE % | -35.93 | |||||
ROA % | -27.32 | |||||
ROIC % | -122.11 | |||||
3-Year ROIIC % | 84.72 | |||||
ROC (Joel Greenblatt) % | -158.3 | |||||
ROCE % | -31.36 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.89 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 0.9 | |||||
EV-to-EBIT | 0.2 | |||||
EV-to-EBITDA | 0.21 | |||||
EV-to-Revenue | -0.36 | |||||
EV-to-Forward-Revenue | 0.41 | |||||
EV-to-FCF | 0.26 | |||||
Price-to-GF-Value | 1.51 | |||||
Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 1.06 | |||||
| Price-to-Net-Cash | 1.09 | |||||
Earnings Yield (Greenblatt) % | 500 | |||||
FCF Yield % | -34.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcturus Therapeutics Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 42.354 | ||
| EPS (TTM) ($) | -2.81 | ||
| Beta | 2.761 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.41 | ||
| Volatility % | 79.83 | ||
| 14-Day RSI | 31.92 | ||
| 14-Day ATR ($) | 0.45775 | ||
| 20-Day SMA ($) | 6.91725 | ||
| 12-1 Month Momentum % | -45.64 | ||
| 52-Week Range ($) | 5.85 - 24.17 | ||
| Shares Outstanding (Mil) | 28.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcturus Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcturus Therapeutics Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 16:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 24 days | ||
| General meeting for 2026 | 2026-06-05 09:00 | 8.04 (+6.07%) | ||
| Guidance call for 2026 | 2026-06-04 09:20 | 7.60 (+0.26%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 9.13 (+7.79%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 9.13 (+7.79%) | ||
| 38th Annual Roth Conference | 2026-03-23 09:30 | 6.63 (-1.78%) | ||
| Guidance call for 2026 | 2026-03-11 11:20 | 7.62 (+1.33%) |
Show
Entries
Arcturus Therapeutics Holdings Inc Frequently Asked Questions
What is Arcturus Therapeutics Holdings Inc(ARCT)'s stock price today?
The current price of ARCT is $6.06. The 52 week high of ARCT is $24.17 and 52 week low is $5.85.
When is next earnings date of Arcturus Therapeutics Holdings Inc(ARCT)?
The next earnings date of Arcturus Therapeutics Holdings Inc(ARCT) is 2026-08-11 Est..
Does Arcturus Therapeutics Holdings Inc(ARCT) pay dividends? If so, how much?
Arcturus Therapeutics Holdings Inc(ARCT) does not pay dividend.
Guru Commentaries on NAS:ARCT
No articles.
Press Release
Articles on Arcturus Therapeutics Holdings Inc
Headlines
See More- 1
Jul 02, 2026
Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy
Seeking Alpha • 9:15am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers